8-K Announcements
6Material company update
May 11, 2026·SEC
Material company update
Apr 9, 2026·SEC
Material company update
Mar 6, 2026·SEC
Adial Pharmaceuticals, Inc.(ADIL)Earnings, Financials & Key Ratios
ADIL•NASDAQ
$2.51
Price updated Jun 27, 2026
AboutAdial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.Show more
- Revenue$0
- EBITDA-$8M+5.9%
- Net Income-$8M+39.6%
- EPS (Diluted)-11.93+32.8%
- ROE-170.73%+47.3%
ADIL Price & Volume
Adial Pharmaceuticals, Inc. (ADIL) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Capital Reserves
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical Trial Funding Shortfall
"Adial Pharmaceuticals remains a high-risk, pre-revenue biotechnology firm entirely dependent on the clinical success of its AD04 program. The company faces significant liquidity pressure as it sustains quarterly operating expenses of approximately $2.0 million without any offsetting revenue streams. Investors should monitor the firm's ability to secure non-dilutive funding, as the current cash position of $4.6 million as of 2026Q1 provides a limited runway for ongoing development activities."
Verdict Logic
the company's accumulated deficit of $92.0 million and reliance on external capital to fund a $2.0 million quarterly burn rate present substantial risks to long-term shareholder value.
ADIL Growth Metrics
Adial Pharmaceuticals, Inc. (ADIL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM13.17%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM72.45%
Return on Capital
10 Years-371.16%
5 Years-243.7%
3 Years-179.87%
Last Year-164.73%
ADIL Recent Earnings
Adial Pharmaceuticals, Inc. (ADIL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)
Q2 2026Latest
May 8, 2026Metric
Actual
Est
EPS
$1.48+45.8%
$2.73
Rev
—
—
Q2 2026
Mar 10, 2026Metric
Actual
Est
EPS
$1.81+13.8%
$2.10
Rev
—
—
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$2.00+11.1%
$2.25
Rev
—
—
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$0.18+18.2%
$0.22
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 8, 2026 | $1.48vs $2.73+45.8% | — |
| Q2 2026 | Mar 10, 2026 | $1.81vs $2.10+13.8% | — |
| Q4 2025 | Nov 13, 2025 | $2.00vs $2.25+11.1% | — |
| Q3 2025 | Aug 13, 2025 | $0.18vs $0.22+18.2% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Adial Pharmaceuticals, Inc. (ADIL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.51 | $2.41M | -0.21 | — | — | -170.73% | — | |
| $3.73 | $64.48M | -2.78 | — | -1070.26% | — | — | |
| $0.64 | $3.57M | -0.32 | — | — | -204.27% | — | |
| $55.08 | $9.18B | 38.52 | -5.25% | 9.78% | 8.82% | — | |
| $25.32 | $4.34B | 11.06 | 11.87% | 34.3% | 35.65% | — | |
| $23.57 | $1.74B | 7.14 | 18.52% | 118.91% | 47.59% | — |
Compare ADIL vs Peers
Adial Pharmaceuticals, Inc. (ADIL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ADIL SEC Filings & Documents
Adial Pharmaceuticals, Inc. (ADIL) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ADIL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ADIL Frequently Asked Questions
Adial Pharmaceuticals, Inc. (ADIL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is ADIL profitable?
Adial Pharmaceuticals, Inc. (ADIL) reported a net loss of $7.8M for fiscal year 2025.
Dividend & Returns
What is ADIL's return on equity?
Adial Pharmaceuticals, Inc. (ADIL) has a return on equity (ROE) of -170.7%. Negative ROE indicates the company is unprofitable.
What is Adial Pharmaceuticals, Inc.'s free cash flow?
Adial Pharmaceuticals, Inc. (ADIL) had negative free cash flow of $6.5M in fiscal year 2025, likely due to heavy capital investments.